Axia Collagenna Skin Care products group has announced that it has reached an agreement with the Prime Pharma marketing and product development Mahonia that were clinically proven to help relieve the symptoms associated with psoriasis
OTTAWA, Ontario, CANADA| August 11, 2011 | Axia Group (Pink Sheets: AGIJ.pk-News) Collagenna Skin Care products, has announced that it has reached an agreement with the Prime Pharma, a subsidiary of TSE listed company allegiance Equity Corporation (TSXV: ANQ.V) www.allegianceequity.com for marketing and product development that Mahonia were clinically proven to help relieve the symptoms associated with psoriasis.
Premier product is the Prime Pharma Relieva over cream, cream of psoriasis counter that has been rewritten in a more effective. The agreement is based on a joint venture for worldwide sales, not for internet marketing of the product retrieved Mahonia, current and future products.
Agreement will enable access Collagenna company patents worldwide, as well as new technology patentable. With Mahonia as a proven active ingredient, first Pharma owns a patented extract with which the company expects to find innovative ways to help distinguish the company from the competition.
Collagenna plans to start clinical trials to validate the preliminary tests and hopes to publish the results in the next 30 days.
The company has started the necessary regulatory documents that will allow Collagenna to the market in Canada and United States Relieva. The company expects this process to take about 60 days. In the meantime will start marketing efforts immediately.
An independent report (research and markets) of the 2004 market prescription psoriasis world concluded this market to grow at a compound annual rate of 23.6% to more than $ 3.1b worldwide by 2009. According to the Global Industry analysts Inc., global medicines market will surpass psoriasis 7.3 billion by 2015.
Skin care products Collagenna is specialized in anti-aging products with an emphasis on stimulating collagen both locally and internally. The company sells its products primarily through its specialized clinical care of the skin through its ever-expanding network of distribution partners.
More details and updates will be provided little and in a timely manner.
Source: Axia Group
No comments:
Post a Comment